MARKET

OGEN

OGEN

Oragenics
AMEX
0.1998
+0.0046
+2.36%
Closed 16:00 11/28 EST
OPEN
0.1968
PREV CLOSE
0.1952
HIGH
0.2030
LOW
0.1920
VOLUME
284.11K
TURNOVER
28.01K
52 WEEK HIGH
0.6251
52 WEEK LOW
0.1825
MARKET CAP
23.47M
P/E (TTM)
-1.4292
1D
5D
1M
3M
1Y
5Y
BRIEF-Oragenics Inc Says On Nov 16, Michael Sullivan, CFO Notified Co That He Would Be Resigning, Effective Dec 14
Reuters · 11/16 22:36
Oragenics to Participate in the 2022 BioFlorida Annual Conference
TAMPA, Fla., October 24, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida Annual Conference, being...
Business Wire · 10/24 20:01
BRIEF-Oragenics Inc Confident In Strategic Direction And Specifically in Plans To Advance N-COV2-1
BRIEF-Oragenics Inc Confident In Strategic Direction And Specifically in Plans To Advance N-COV2-1
Reuters · 09/30 11:42
Oragenics Issues Letter to Shareholders
TAMPA, Fla., September 30, 2022--Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, today issued the following letter to shareholders from its President...
Business Wire · 09/30 11:30
BRIEF-Oragenics Reports Preliminary Data For Intranasal COVID-19 Vaccine Candidate
BRIEF-Oragenics Reports Preliminary Data For Intranasal COVID-19 Vaccine Candidate
Reuters · 08/24 11:07
Oragenics Announces Preliminary Toxicology Data For Intranasal COVID-19 Vaccine Candidate; Says 'N T-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies'
N T-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies Intranasal administration elicits immune responses Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the
Benzinga · 08/24 11:01
Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
TAMPA, Fla., August 24, 2022--Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate
Business Wire · 08/24 11:00
Why Bed Bath & Beyond Is Trading Higher By 12%; Here Are 26 Stocks Moving Premarket
Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 25.2% to $0.54 in pre-market trading. Bird secured permit extensions and expanded to new U.S. cities.
Benzinga · 08/24 10:40
More
About OGEN
Oragenics, Inc. is a development-stage company that is focused on fighting infectious diseases, including coronaviruses and multidrug-resistant organisms. The Company's lead product, NT-CoV2-1, is an intranasal immunization vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. Its other product candidates include Terra CoV-2 and Antibiotics. Terra CoV-2 is an intramuscular vaccine candidate (plasmid + adjuvant) to provide long-lasting immunity against SARS-CoV-2. Antibiotics is a semi-synthetic analogs of MU1140, which is a member of lantibiotic class of antibiotics. The Company, through its wholly owned subsidiary, Noachis Terra, Inc. (Noachis Terra), is engaged in the research and development of its Terra CoV-2 and NT-CoV2-1 vaccine product candidates. It is also developing semi-synthetic lantibiotic analogs that may be effective against systemic Gram-positive multidrug infections, and analogs that may be effective in treating Gram negative infections.

Webull offers kinds of Oragenics Inc stock information, including AMEX:OGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OGEN stock methods without spending real money on the virtual paper trading platform.